dc.contributor.author | Chorlton, J | en_US |
dc.contributor.author | Hollowood, Z | en_US |
dc.contributor.author | Dyer, C | en_US |
dc.contributor.author | Lockhart, D | en_US |
dc.contributor.author | Boekman, P | en_US |
dc.contributor.author | McCafferty, K | en_US |
dc.contributor.author | Coffey, P | en_US |
dc.contributor.author | Marelli-Berg, F | en_US |
dc.contributor.author | Martin, J | en_US |
dc.date.accessioned | 2023-12-06T11:52:15Z | |
dc.date.available | 2022-07-18 | en_US |
dc.date.issued | 2022 | en_US |
dc.identifier.other | ARTN 101604 | |
dc.identifier.other | ARTN 101604 | |
dc.identifier.other | ARTN 101604 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/92669 | |
dc.relation.ispartof | ECLINICALMEDICINE | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | COVID-19 | en_US |
dc.subject | SARs-COV-2 | en_US |
dc.subject | AZD1656 | en_US |
dc.subject | Glucokinase activator | en_US |
dc.subject | Diabetes | en_US |
dc.subject | Regulatory T cells | en_US |
dc.subject | Tregs | en_US |
dc.subject | Immune | en_US |
dc.subject | Clinical trial | en_US |
dc.subject | ARCADIA | en_US |
dc.subject | Cytokine | en_US |
dc.subject | Immunophenotyping | en_US |
dc.title | A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial- implications for therapeutic immune modulation | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1016/j.eclinm.2022.101604 | en_US |
pubs.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000864521100007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 51 | en_US |